PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[xNmlEPTB;MD6wNlI4PiEQvF2= MmDNV2FPT0WU
CHP-212 NYHNbYI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W2T2lEPTB;MD6wNlg5PSEQvF2= MnTtV2FPT0WU
EoL-1-cell MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMESxOVIh|ryP Mnn3V2FPT0WU
DU-4475 NEPRe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMEe1PVkh|ryP M2C5NnNCVkeHUh?=
MMAC-SF MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LK[GlEPTB;MD6xNFk4PCEQvF2= MnvZV2FPT0WU
AGS NVX2OJNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITHRVVKSzVyPUCuNVE4OTNizszN M4j3fHNCVkeHUh?=
M14 NGLRfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj3OnZKSzVyPUCuNVU1PjhizszN MmDFV2FPT0WU
CP50-MEL-B MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPaTWM2OD1yLkG3NlU1KM7:TR?= MnnKV2FPT0WU
C32 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSwSmdvUUN3ME2wMlE6ODd{IN88US=> MVjTRW5ITVJ?
KMOE-2 NEPYVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMUm3PVUh|ryP MYTTRW5ITVJ?
A101D NGDtN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMkG0JO69VQ>? NGXuVJNUSU6JRWK=
KM12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[4coNvUUN3ME2wMlI1ODV5IN88US=> M2rZT3NCVkeHUh?=
HSC-4 NUHvXlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjDWI94UUN3ME2wMlI1Ozl3IN88US=> NVT1RmxuW0GQR1XS
NOMO-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMkW3OFIh|ryP M3i3eXNCVkeHUh?=
MZ7-mel NXjQR3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPzeFNKSzVyPUCuNlY{PCEQvF2= NYXaNpBkW0GQR1XS
ACN NXTtNZJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGzSZJOUUN3ME2wMlI3PzN5IN88US=> MVzTRW5ITVJ?
MEL-HO MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMke2OVIh|ryP M4HOOHNCVkeHUh?=
BHT-101 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMki2NFYh|ryP M2nUSnNCVkeHUh?=
SK-MEL-28 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\LbmlEPTB;MD6zNFQxQSEQvF2= M4PDeXNCVkeHUh?=
KG-1 M2jRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwM{C2Olgh|ryP M{TzeXNCVkeHUh?=
COLO-679 NFX1S5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n1dmlEPTB;MD6zNlczKM7:TR?= Mm\0V2FPT0WU
SK-MEL-24 NHXU[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwM{K4NVMh|ryP MWnTRW5ITVJ?
G-361 M3jBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHLTWM2OD1yLkO2O|k2KM7:TR?= Ml20V2FPT0WU
KY821 M322bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjWTWM2OD1yLkO3PVEh|ryP MUfTRW5ITVJ?
KASUMI-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;QTVZKSzVyPUCuN|k6KM7:TR?= MXnTRW5ITVJ?
HL-60 NF3CfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjSOIFQUUN3ME2wMlQyOTB5IN88US=> NEjwR3NUSU6JRWK=
K5 M3flVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13ycmlEPTB;MD60N|EyPyEQvF2= M{HMUXNCVkeHUh?=
KU812 M4TJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjFbm5SUUN3ME2wMlQ2Ojl7IN88US=> MXfTRW5ITVJ?
SH-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvQTWM2OD1yLkS2NlU3KM7:TR?= Mm\sV2FPT0WU
HTC-C3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjSXHRKSzVyPUCuOFY2OzFizszN M2HTNnNCVkeHUh?=
CP66-MEL M3m4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwNEi4NFkh|ryP NFyyepFUSU6JRWK=
WM-115 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNEmyOVch|ryP MVTTRW5ITVJ?
A2780 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vvXmlEPTB;MD60PVgzOyEQvF2= MmDsV2FPT0WU
P12-ICHIKAWA NUTTSmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwNkGyNlEh|ryP Ml7IV2FPT0WU
HMV-II MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwNkS0OlUh|ryP NXvXV5RCW0GQR1XS
HT-144 NXfrXFhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNkS2OVch|ryP NWXRXJNzW0GQR1XS
LB2518-MEL M1vmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwN{G2N|Ih|ryP NUnwT|NOW0GQR1XS
NCI-SNU-1 NHTMXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;6VJNKSzVyPUCuO|U1OzNizszN M2PpOHNCVkeHUh?=
C2BBe1 M2HUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwOEGwNlMh|ryP NVG5UHFDW0GQR1XS
PSN1 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLU[YhKSzVyPUCuPVYyQTZizszN MmjxV2FPT0WU
UACC-257 M33KWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLTTWM2OD1yLkm2OFc{KM7:TR?= NIT3NlhUSU6JRWK=
RVH-421 NHL4VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fV[mlEPTB;MD65O|E5KM7:TR?= M4LNO3NCVkeHUh?=
GP5d NFvKOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHoTWM2OD1yLkm4N|A5KM7:TR?= M3X1enNCVkeHUh?=
TYK-nu NEnVPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPxT|hKSzVyPUGuNFMyPzJizszN MV7TRW5ITVJ?
SK-N-AS M2XsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfJUpVKSzVyPUGuNFc6PDdizszN MYDTRW5ITVJ?
SW620 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLCTWM2OD1zLkGzOVM1KM7:TR?= NEDXVnpUSU6JRWK=
HuP-T4 NUSxbpN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwMUizOVkh|ryP MVXTRW5ITVJ?
A549 NGK3TVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWzWVBqUUN3ME2xMlE6PTd4IN88US=> NVvVNWxvW0GQR1XS
Mewo MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zNfWlEPTB;MT6yNFI4PiEQvF2= NWe3coFNW0GQR1XS
ONS-76 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwMkKwOFkh|ryP NHLzPYtUSU6JRWK=
SK-MEL-1 M{TFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nrfGlEPTB;MT6yN|QyQSEQvF2= NXHae5l1W0GQR1XS
RCM-1 NH7kb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWzTWM2OD1zLkK0NFQ4KM7:TR?= NXzIbGp1W0GQR1XS
H-EMC-SS M4r2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrzTWM2OD1zLkK5OlA5KM7:TR?= NEGzcoZUSU6JRWK=
NCI-H2291 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jUNWlEPTB;MT6zNlU{PiEQvF2= MlHEV2FPT0WU
SW1463 NFy5RWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnjV|dKSzVyPUGuN|M4OjFizszN NFi4Zo9USU6JRWK=
LS-411N M1;vS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Tkb2lEPTB;MT60NFUyPyEQvF2= NXzFXlJzW0GQR1XS
BV-173 M4HlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\kTWM2OD1zLkS0NFE2KM7:TR?= NEjMc49USU6JRWK=
LS-513 NVPTT2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XhSWlEPTB;MT60OVE6OiEQvF2= MVTTRW5ITVJ?
LoVo MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWzZ5RsUUN3ME2xMlQ3Ozl7IN88US=> NVnqeHpmW0GQR1XS
HO-1-N-1 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwNUG2N|Qh|ryP NHLCWXVUSU6JRWK=
ML-2 NXS3OYJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwNUK4Olgh|ryP M4nRcnNCVkeHUh?=
NCI-H1437 M4LhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC1TWM2OD1zLkW1Nlc2KM7:TR?= NIrkTo9USU6JRWK=
SW1116 NE\BTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknZTWM2OD1zLkW2N|k5KM7:TR?= M1HjPXNCVkeHUh?=
A4-Fuk NEniZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7OTWM2OD1zLkW3NFQ2KM7:TR?= NHHKNVJUSU6JRWK=
HD-MY-Z NFTGU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS0NlI4UUN3ME2xMlU4Ozd4IN88US=> NYny[3NZW0GQR1XS
SK-MEL-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwNUe0OVkh|ryP MXTTRW5ITVJ?
RT-112 NYjwbWlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwNUi5OVIh|ryP MXfTRW5ITVJ?
COLO-829 M3r1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\zbIRKSzVyPUGuOlIzOzJizszN M1;nWHNCVkeHUh?=
OVCAR-5 M4DNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHzcJQ5UUN3ME2xMlc4Pjh5IN88US=> MXjTRW5ITVJ?
NB69 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnRSHBWUUN3ME2xMlc5PDZ7IN88US=> NFfFdFZUSU6JRWK=
NCI-H292 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG3TWM2OD1zLki2Olk6KM7:TR?= NUDjPIU1W0GQR1XS
LOXIMVI MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwOEm0Nlch|ryP MV3TRW5ITVJ?
BPH-1 M2fNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLwTWM2OD1zLki5OVkyKM7:TR?= NUftWVJsW0GQR1XS
A375 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D1VWlEPTB;MT64PVcyPCEQvF2= M1XHSHNCVkeHUh?=
LCLC-97TM1 NHGzZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjjTWM2OD1zLkmyNlU3KM7:TR?= NYPYXlFqW0GQR1XS
RXF393 NXHDO2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL2Xnc6UUN3ME2xMlk4QDh5IN88US=> M2jFOXNCVkeHUh?=
HCC70 NUH2bJU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnFNFBFUUN3ME2yMlAzPDJ4IN88US=> MXnTRW5ITVJ?
EM-2 NVr5So0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPVTWM2OD1{LkC3NVk5KM7:TR?= NUS0XJhLW0GQR1XS
MZ2-MEL MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJwMUGxNlch|ryP MU\TRW5ITVJ?
HN NEfCXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\2T2lEPTB;Mj6xOlI4QCEQvF2= M4\KS3NCVkeHUh?=
A2058 M3jCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXxTWM2OD1{LkG5Nlc6KM7:TR?= M3P1XXNCVkeHUh?=
NB7 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LF[2lEPTB;Mj6zOFA5PiEQvF2= M2SyNHNCVkeHUh?=
DOK NITvc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzTXplnUUN3ME2yMlM2Pzd|IN88US=> M1;icHNCVkeHUh?=
CAL-27 M3Gxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwM{myN|Yh|ryP MX3TRW5ITVJ?
BB65-RCC Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PrVGlEPTB;Mj60NFY4PCEQvF2= MnHXV2FPT0WU
RD MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf5c|MxUUN3ME2yMlQ1PzJ|IN88US=> MkK2V2FPT0WU
KNS-62 NYXy[Fk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwNUGxOlQh|ryP NWXMRXZtW0GQR1XS
EW-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwNU[zN|kh|ryP MUDTRW5ITVJ?
DB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJwNUi3PFgh|ryP M{PJd3NCVkeHUh?=
HCC2218 NXjXelRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvMTWM2OD1{Lk[0O|c5KM7:TR?= M37hOHNCVkeHUh?=
L-363 M17tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzIPFJKSzVyPUKuO|Q{PyEQvF2= MmmzV2FPT0WU
CHL-1 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwOEC3PFUh|ryP MVLTRW5ITVJ?
BFTC-905 M2fQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\I[mlEPTB;Mj64NlU{KM7:TR?= NHPnPHJUSU6JRWK=
HCE-T M2n6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzTTWM2OD1{LkizNlY1KM7:TR?= Mk\hV2FPT0WU
COLO-792 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJwOESwNlch|ryP NXjnU5VoW0GQR1XS
LB2241-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPFN|BKSzVyPUKuPFU5QTNizszN M3Wzb3NCVkeHUh?=
CAL-39 M2LqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfxUFlKSzVyPUKuPFk6QTlizszN M2\RdXNCVkeHUh?=
T-24 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJwOUGxNVIh|ryP NYKxfYh6W0GQR1XS
NCI-H727 NGD1TVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3yTWM2OD1{LkmxO|k3KM7:TR?= MkfsV2FPT0WU
Ca9-22 M3zkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjJcHp5UUN3ME2yMlk4OjV3IN88US=> NYm5UJBJW0GQR1XS
MIA-PaCa-2 NXO4c45NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r1bmlEPTB;Mz6wNFc5OSEQvF2= NIHmeHpUSU6JRWK=
HT-1080 M1fFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvKV49rUUN3ME2zMlAyQTl5IN88US=> M1nVd3NCVkeHUh?=
D-423MG Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDtdWxKUUN3ME2zMlA4PzV|IN88US=> MWfTRW5ITVJ?
LAMA-84 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTm[o5HUUN3ME2zMlE{PThizszN MnvTV2FPT0WU
SW780 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXxTWM2OD1|LkG0NlI6KM7:TR?= NHPDcYlUSU6JRWK=
KU-19-19 NEPaVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLXUHZKSzVyPUOuNVcxOzRizszN M1iwNXNCVkeHUh?=
COLO-741 NYn6ZmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH5TWM2OD1|LkG4Olc{KM7:TR?= NFfGWoZUSU6JRWK=
HSC-3 NY\oS|k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvNTnBMUUN3ME2zMlI{OTVzIN88US=> M3fybnNCVkeHUh?=
SN12C MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXGTWM2OD1|LkK0O|AyKM7:TR?= M4HzcXNCVkeHUh?=
786-0 M{Hhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwMkeyOFMh|ryP MXLTRW5ITVJ?
GAK M4nCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfXSlA4UUN3ME2zMlMzPTZzIN88US=> M{nKbHNCVkeHUh?=
PANC-03-27 M37aeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTQPWN5UUN3ME2zMlM2ODR3IN88US=> NHvmVndUSU6JRWK=
CTB-1 M3zqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfmbVJKSzVyPUOuOFcxPDdizszN Mn;sV2FPT0WU
A427 M3TEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTaR|l[UUN3ME2zMlU6PTV4IN88US=> M3X3enNCVkeHUh?=
EGI-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNwNkC1PFMh|ryP NEDiTJBUSU6JRWK=
U-2-OS NUHobmRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNwNkeyOVYh|ryP MmrrV2FPT0WU
NCI-SNU-5 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP2[INSUUN3ME2zMlY4PzNizszN MnPQV2FPT0WU
SK-LU-1 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TZOmlEPTB;Mz62PFc6QCEQvF2= M3HwZ3NCVkeHUh?=
697 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXLUGVKSzVyPUOuOlk3ODNizszN Mkm1V2FPT0WU
HPAF-II M{frNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT6TWM2OD1|Lke1OFkh|ryP NILyZoVUSU6JRWK=
NCI-H2087 NWPtbJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTyS4h{UUN3ME2zMlg1Pjd{IN88US=> MXfTRW5ITVJ?
SK-MEL-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\Gd2lEPTB;Mz64OVE2PCEQvF2= MWfTRW5ITVJ?
CGTH-W-1 NVTCSFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNwOEW3NlUh|ryP MmrPV2FPT0WU
8505C MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mzeWlEPTB;Mz65NFA4QCEQvF2= M3;o[HNCVkeHUh?=
GAMG NYHlb41TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KxfWlEPTB;ND6wNlM4PyEQvF2= NXL1RZFDW0GQR1XS
SW626 NYDNbXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULhT2hKUUN3ME20MlA1PDhizszN NUn4VZR{W0GQR1XS
CAL-62 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\kOmlEPTB;ND6wO|Q{KM7:TR?= M1\Sb3NCVkeHUh?=
MHH-PREB-1 M1yzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\jTWM2OD12LkGyNVEyKM7:TR?= NX:yOVNNW0GQR1XS
RPMI-7951 M4XTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fmeWlEPTB;ND6yOVU5QSEQvF2= MYLTRW5ITVJ?
HOP-92 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRwMkW2O{DPxE1? M1LTOHNCVkeHUh?=
MDA-MB-231 M{CxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzYR21xUUN3ME20MlI6OjJ|IN88US=> M13Yc3NCVkeHUh?=
LAN-6 M{HBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnnd4FYUUN3ME20MlMyPjN5IN88US=> MYLTRW5ITVJ?
ALL-PO Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnDPG9KSzVyPUSuN|YyPTZizszN MVjTRW5ITVJ?
HH NEX3TpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRwNEG1PVch|ryP NXPUfmJtW0GQR1XS
IGROV-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTRwNEWxO|Eh|ryP NH\1T3ZUSU6JRWK=
NCI-H358 M{L6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD6TWM2OD12LkS1N|g2KM7:TR?= NX;NVVB{W0GQR1XS
NB5 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP3W4ZKSzVyPUSuOlA{PjlizszN NFG2SXZUSU6JRWK=
NCI-H747 M2fld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;RTWM2OD12Lk[4PFA4KM7:TR?= NYmxfppzW0GQR1XS
NH-12 NYTTfmtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf5epdjUUN3ME20MlcyPjJ3IN88US=> M2DrXHNCVkeHUh?=
LB1047-RCC M1i2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K1d2lEPTB;ND63N|gyPSEQvF2= NFPWUWtUSU6JRWK=
EFO-27 NIrvWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPOTWM2OD12Lke4OlY4KM7:TR?= MmTPV2FPT0WU
EPLC-272H NHvD[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRwOUm2Olkh|ryP MWrTRW5ITVJ?
CAL-54 NIO3cnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[2N|dGUUN3ME21MlAzPjl3IN88US=> Mnf0V2FPT0WU
H4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzGTWM2OD13LkC0NlU2KM7:TR?= MXzTRW5ITVJ?
MOLT-13 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjsRZk5UUN3ME21MlA3Pzd4IN88US=> M37CfnNCVkeHUh?=
CAL-33 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrPfVVKSzVyPUWuNVI{OTdizszN NI\qO2NUSU6JRWK=
23132-87 NIrhe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXDTWM2OD13LkG2PFczKM7:TR?= MnLNV2FPT0WU
UM-UC-3 NIDjbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTVwMUiwOFch|ryP M4DnOXNCVkeHUh?=
HuH-7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHLfoNKSzVyPUWuNlcyPDdizszN MonsV2FPT0WU
BCPAP NHX4[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTQO2dKSzVyPUWuN|I6PjlizszN NHfjNIdUSU6JRWK=
AsPC-1 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTVwM{[3OlMh|ryP MYjTRW5ITVJ?
NCI-H1155 NUHtdGRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoThTWM2OD13LkSwNFUyKM7:TR?= MoXqV2FPT0WU
GT3TKB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXFOVJKSzVyPUWuOFY2QThizszN NIrRS|VUSU6JRWK=
HCC2998 M4e4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\Vc2lEPTB;NT60PVExQSEQvF2= MYHTRW5ITVJ?
NUGC-3 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXPTWM2OD13LkS5N|AzKM7:TR?= NEjwZo1USU6JRWK=
Hs-578-T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTVwNUO3PVQh|ryP MWrTRW5ITVJ?
FADU MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXPTWM2OD13LkW1O|I3KM7:TR?= Ml7KV2FPT0WU
NBsusSR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPXcnBRUUN3ME21MlU4OTV3IN88US=> MV7TRW5ITVJ?
ME-180 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHizOmFKSzVyPUWuOVgxQTJizszN M{m5cXNCVkeHUh?=
SW1710 M1zCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G0[mlEPTB;NT62NVY2PCEQvF2= NYnzZXljW0GQR1XS
HuP-T3 M17Y[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXUV|dKSzVyPUWuOlIxOjlizszN MWXTRW5ITVJ?
HOS MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTVwNkK5NlMh|ryP MVvTRW5ITVJ?
PA-1 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi3VlRKSzVyPUWuOlQzPjVizszN NFv2UlZUSU6JRWK=
LU-99A NYTJOFB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfETWM2OD13Lk[2OFUyKM7:TR?= M{\pPXNCVkeHUh?=
RS4-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rFd2lEPTB;NT62Olc4PSEQvF2= M17KOHNCVkeHUh?=
TE-8 M2W3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTVwNki1N|ch|ryP NYK4bWI2W0GQR1XS
RERF-LC-MS NWmyXmNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVwNki4NFMh|ryP MnflV2FPT0WU
MEL-JUSO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKyTWM2OD13LkezO|gh|ryP M37qTXNCVkeHUh?=
SK-MES-1 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LpO2lEPTB;NT64N|UzQCEQvF2= MWXTRW5ITVJ?
D-263MG M4LSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVwOEizOVEh|ryP NVPxXHBxW0GQR1XS
NB10 M{XFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3rTWM2OD13Lki5OFYh|ryP MWfTRW5ITVJ?
SK-HEP-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTTTWM2OD13LkmzOFcyKM7:TR?= MlPDV2FPT0WU
HT-29 NGe1Z3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHqWXpKSzVyPUWuPVgyOThizszN MVXTRW5ITVJ?
KYSE-140 NXfBVWxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP0OWZ{UUN3ME22MlAzOTh{IN88US=> MXnTRW5ITVJ?
NCI-H1666 NYf3NZd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL6TWM2OD14LkC4OFYyKM7:TR?= M{XHXHNCVkeHUh?=
NCI-H1304 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTZwMUm5OEDPxE1? M4ruXHNCVkeHUh?=
RPMI-8866 NGflSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTZwMkGzNVMh|ryP NETsZWtUSU6JRWK=
MV-4-11 NHz0UWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\q[|hZUUN3ME22MlI{OTl7IN88US=> MVPTRW5ITVJ?
A431 NIXzS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzueFNKSzVyPU[uNlQzQTZizszN MVPTRW5ITVJ?
PANC-10-05 NFLtbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTZwMkizOlMh|ryP M2DiZ3NCVkeHUh?=
TK10 M2jiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvDVmgzUUN3ME22MlMzPjB2IN88US=> M2\sXXNCVkeHUh?=
NCI-H1975 M4nvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfkW3hKSzVyPU[uOFczOTVizszN MYnTRW5ITVJ?
A172 NY[1c2NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjJflZKSzVyPU[uOFkyPzZizszN NGrCbpJUSU6JRWK=
D-566MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DpWWlEPTB;Nj61OFMxOyEQvF2= M{L2RXNCVkeHUh?=
NCI-H2122 NGHRS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInhfXJKSzVyPU[uOlE2OjhizszN NVnkRXYyW0GQR1XS
COR-L105 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS1TWM2OD14Lk[1Nlc2KM7:TR?= M4Pye3NCVkeHUh?=
AN3-CA Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDrTWM2OD14Lk[4OlQyKM7:TR?= M{nKenNCVkeHUh?=
Calu-6 NX\KZWpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTZwN{m2PVgh|ryP NY\mXVZuW0GQR1XS
HCT-116 M4Dye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTZwOEGyOlQh|ryP Mmn4V2FPT0WU
MHH-NB-11 NVjCZmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED0R25KSzVyPU[uPFUxODJizszN NUL5c2VGW0GQR1XS
MFE-280 M3rrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[0PXZKSzVyPU[uPFU6QDNizszN M1PCN3NCVkeHUh?=
SW1088 NV7JTFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLBTWM2OD14LkmxPVE{KM7:TR?= NWrE[m5rW0GQR1XS
SW48 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljUTWM2OD14Lkm0OVEh|ryP M{n5bHNCVkeHUh?=
HuCCT1 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETJXlRKSzVyPUeuNFExOzdizszN MV\TRW5ITVJ?
ACHN NXzBVGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTdwMEK5OFMh|ryP NXq2UIxsW0GQR1XS
8305C M2r4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTdwMEm5PVUh|ryP MY\TRW5ITVJ?
DoTc2-4510 M4nlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTdwMUKxOUDPxE1? NUC0TIkzW0GQR1XS
COR-L23 NFfXVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTdwMkS0NkDPxE1? MmqyV2FPT0WU
SK-MEL-30 NGm2OI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPwfHdKSzVyPUeuNlUxQDNizszN MoDMV2FPT0WU
BE-13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPkOo5SUUN3ME23MlM{QDN2IN88US=> NH7RXmZUSU6JRWK=
GR-ST M3rMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTlTWM2OD15LkSwNVc1KM7:TR?= NWLWV41uW0GQR1XS
LU-135 NH3OPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DYXGlEPTB;Nz61OVk{QSEQvF2= M33VSHNCVkeHUh?=
U-266 NH;pOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTdwNU[yPFYh|ryP MmrHV2FPT0WU
NCI-H1355 M2nVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLrPFdyUUN3ME23MlU5PjN3IN88US=> NUj5UYRkW0GQR1XS
NB14 M2jMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn76TWM2OD15Lk[2OlQzKM7:TR?= Mlf4V2FPT0WU
SCC-25 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDnTWM2OD15LkewPUDPxE1? MV\TRW5ITVJ?
COLO-678 M1THPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTdwN{GwO|Yh|ryP M3vnTHNCVkeHUh?=
TGBC1TKB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzofHRKSzVyPUeuPFk{QThizszN NH7nTmdUSU6JRWK=
IST-MEL1 NE\QR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXITWM2OD16LkCwOFA3KM7:TR?= MmHLV2FPT0WU
ECC10 NUDNXoxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv2TWM2OD16LkCzN|k2KM7:TR?= MnLKV2FPT0WU
EW-16 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33FWWlEPTB;OD6wPFQ1PSEQvF2= Mn3NV2FPT0WU
DOHH-2 M1\DbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fE[mlEPTB;OD6yNFA6PSEQvF2= NYHYNGJ4W0GQR1XS
NCI-H1581 M1KxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPLZnRKSzVyPUiuNlY{OjNizszN NUnESm9xW0GQR1XS
TE-5 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vXNmlEPTB;OD60NlQzQSEQvF2= MlXHV2FPT0WU
CAKI-1 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fyUGlEPTB;OD61O|IzOiEQvF2= MWTTRW5ITVJ?
A673 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLROINwUUN3ME24MlY{OjB{IN88US=> MkDOV2FPT0WU
CAL-12T NHnSUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm0TWM2OD16Lk[1O|U{KM7:TR?= MlrtV2FPT0WU
DBTRG-05MG NVzVOWxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz4TWM2OD16Lke0PFU6KM7:TR?= NH;qe4ZUSU6JRWK=
SK-N-FI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;JTWM2OD16LkixN|c6KM7:TR?= MXrTRW5ITVJ?
K-562 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Dtb2lEPTB;OD64N|k2PyEQvF2= NGXZbW1USU6JRWK=
SBC-1 NUjP[IhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRThwOE[2OFUh|ryP NGSxdWJUSU6JRWK=
ES4 M3jZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7wbWtIUUN3ME24Mlg3QDh2IN88US=> NFzUZ|BUSU6JRWK=
MS-1 M2LLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTjepBKSzVyPUiuPFc2OTdizszN MXfTRW5ITVJ?
RKO M{TiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PW[WlEPTB;OD64PVA2PyEQvF2= NWT3bYs5W0GQR1XS
NCI-H1693 NVnzbXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu3eGNKSzVyPUiuPVIyPyEQvF2= MknKV2FPT0WU
SW954 NIjDeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXewNG1KUUN3ME24Mlk3QTd6IN88US=> MnraV2FPT0WU
SK-UT-1 NX;oWYdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTSUYIyUUN3ME24Mlk4Pjh|IN88US=> NWnoT2JyW0GQR1XS
T98G MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\BZYlKSzVyPUiuPVk5PDZizszN M2PzUHNCVkeHUh?=
NCI-H2126 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjsUnRtUUN3ME25MlAxQDJ4IN88US=> MlfMV2FPT0WU
TE-12 NUT4cZBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTvZ3c3UUN3ME25MlA{OzZ5IN88US=> NGjFRmRUSU6JRWK=
DK-MG M4DZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rabGlEPTB;OT6yNVE6OSEQvF2= MYPTRW5ITVJ?
MEG-01 NGn4cG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTlwMkS5N|Eh|ryP MUHTRW5ITVJ?
HCC1937 NGjwfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vybGlEPTB;OT6yPVA6OSEQvF2= MWrTRW5ITVJ?
MKN45 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjVeHVLUUN3ME25MlQ2ODZ3IN88US=> MX\TRW5ITVJ?
NCI-H1792 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnJdlRVUUN3ME25MlQ2OjF7IN88US=> NEn6U4FUSU6JRWK=
SW1417 NE\se|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\6c5NKSzVyPUmuOVY5OzdizszN MYHTRW5ITVJ?
639-V NEPGO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTlwNkSzPFgh|ryP NW\QfI43W0GQR1XS
P30-OHK M3W3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NECzeohKSzVyPUmuOlU{OTZizszN MlfoV2FPT0WU
YKG-1 M3Py[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD17Lke1NFM{KM7:TR?= NUnOeI12W0GQR1XS
KGN M1LvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO1RmxKSzVyPUmuPFM4QTVizszN NXz0O3lUW0GQR1XS
MSTO-211H NG\iSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3SNoFKSzVyPUmuPVU2OjlizszN Mk\sV2FPT0WU
NCI-H1573 NYTiTopoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP0TWM2OD1zMD6xOVc1KM7:TR?= NIe3SVBUSU6JRWK=
NCI-H720 NIXnO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;VfWRKSzVyPUGwMlE6QDlizszN MV3TRW5ITVJ?
KARPAS-45 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;oTWM2OD1zMD6yO|k2KM7:TR?= NG[wPJRUSU6JRWK=
MDA-MB-175-VII NXO1NVRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzuWpNrUUN3ME2xNE41QCEQvF2= MWTTRW5ITVJ?
SK-NEP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[0O|VKSzVyPUGwMlQ6QDFizszN NYrqUI1sW0GQR1XS
MKN28 NFnvU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK2boV[UUN3ME2xNE42OThizszN M1WyU3NCVkeHUh?=
KYSE-520 NEj0dmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W2PWlEPTB;MUCuOVIh|ryP M2LHN3NCVkeHUh?=
KE-37 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFyLkWyO|Ih|ryP MnXCV2FPT0WU
VA-ES-BJ NWfR[WV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnGc|RKSzVyPUGwMlU3PyEQvF2= Mlr4V2FPT0WU
CCRF-CEM MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f6XGlEPTB;MUCuOVY5PCEQvF2= MlPvV2FPT0WU
GMS-10 MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e3S2lEPTB;MUCuOlA6PCEQvF2= NXLneYN{W0GQR1XS
NCI-H1623 NUDvb4lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDDN2RlUUN3ME2xNE43Ozd7IN88US=> M{LxTXNCVkeHUh?=
NEC8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS1NVZKSzVyPUGwMlc4PzNizszN NI[zNJlUSU6JRWK=
MOLT-16 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3RTWM2OD1zMD64NVE{KM7:TR?= MoPlV2FPT0WU
DJM-1 NEj2eJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1iwTGlEPTB;MUGuNFM4QSEQvF2= M4fhZXNCVkeHUh?=
U251 NUDG[49MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjXZWN[UUN3ME2xNU4xPDJizszN Mom2V2FPT0WU
SBC-5 NUjrWpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInFd3BKSzVyPUGxMlE1PjdizszN MWfTRW5ITVJ?
SW756 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFzLkKxOVQh|ryP MoXjV2FPT0WU
KS-1 NG\kbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\ld|RKSzVyPUGxMlI3OTlizszN NYDzT2ZQW0GQR1XS
SF295 NITaNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFzLkOxNFQh|ryP MXrTRW5ITVJ?
YH-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DvbWlEPTB;MUGuN|I3PyEQvF2= MmnmV2FPT0WU
SW837 NXy1OYJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFzLkO1NFYh|ryP MXfTRW5ITVJ?
KYSE-450 NIjIcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DjTmlEPTB;MUGuOFA2PyEQvF2= MlrCV2FPT0WU
KYSE-180 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvYTWM2OD1zMT60PFIh|ryP MWrTRW5ITVJ?
S-117 NY[3WXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjNNIlqUUN3ME2xNU41QDl4IN88US=> NFzuV2tUSU6JRWK=
KOSC-2 NIPDS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm5TWM2OD1zMT62NlIzKM7:TR?= NXPTRnpyW0GQR1XS
KYSE-270 M{PkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFzLki3OFUh|ryP NYLDTYEyW0GQR1XS
D-336MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3VTWM2OD1zMT65NFc2KM7:TR?= NGnDR29USU6JRWK=
KALS-1 NGniVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS5VXZKSzVyPUGyMlAxOTZizszN NYP0O|VSW0GQR1XS
LB373-MEL-D Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF{LkC1N|Mh|ryP NYLWV|U3W0GQR1XS
HLE NWTPR5l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF{LkC1PFUh|ryP MoHsV2FPT0WU
SJSA-1 M4mzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzqTWM2OD1zMj6wO|M2KM7:TR?= MoDrV2FPT0WU
SW1990 MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF{LkC5NVEh|ryP MXvTRW5ITVJ?
NOS-1 NFzueFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvzZmh1UUN3ME2xNk4yOzV{IN88US=> MkfzV2FPT0WU
GI-ME-N MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrGOXFHUUN3ME2xNk4zOTZ|IN88US=> Mmq2V2FPT0WU
NCI-H1703 NWr1NJp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j1VGlEPTB;MUKuNlYyPiEQvF2= M{n4RXNCVkeHUh?=
ES7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzqNo5vUUN3ME2xNk4zPzJ2IN88US=> NYf0dGllW0GQR1XS
KYSE-510 NUG3OYJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrJTWM2OD1zMj61NFc6KM7:TR?= NFzldm9USU6JRWK=
BHY NV;h[pJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP1TWM2OD1zMj61N|A4KM7:TR?= M1;NNnNCVkeHUh?=
TCCSUP M{T5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XnSGlEPTB;MUKuOVc2PyEQvF2= M1LsXXNCVkeHUh?=
HSC-2 NV73ZpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF{LkW5PVYh|ryP NXjzd|doW0GQR1XS
BEN NV[1bmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XSNGlEPTB;MUKuOlE1OyEQvF2= M3LUZnNCVkeHUh?=
769-P MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHkSGhKSzVyPUGyMlc6OjRizszN MoDkV2FPT0WU
HT NF6xeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i3XmlEPTB;MUKuPFM1PiEQvF2= NFPkWXNUSU6JRWK=
LXF-289 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHicWRKSzVyPUGyMlk2OzFizszN MVLTRW5ITVJ?
OVCAR-3 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDQTWM2OD1zMj65OVY4KM7:TR?= Mn7sV2FPT0WU
ATN-1 NGLjdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LvbmlEPTB;MUOuNFE5PCEQvF2= M4jr[HNCVkeHUh?=
8-MG-BA MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF|LkC0OVUh|ryP NWnhWXFTW0GQR1XS
SW13 M2\keWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF|LkGxOlUh|ryP MnS1V2FPT0WU
NCI-H1092 M{\zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF|LkG2NkDPxE1? NXHZXlZpW0GQR1XS
OAW-42 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ixV2lEPTB;MUOuNVk{PyEQvF2= NU\MWHF6W0GQR1XS
NCI-H2452 NWTQV5VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXITWM2OD1zMz6yNVc2KM7:TR?= MnH5V2FPT0WU
CAPAN-1 NGPTPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PoUWlEPTB;MUOuOVUyPCEQvF2= M2XDfXNCVkeHUh?=
NCI-H2009 NWLsOYVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF|LkW5NVkh|ryP MmqyV2FPT0WU
SF268 NHXwbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF|Lk[zNlYh|ryP MUDTRW5ITVJ?
GCIY MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHXTWM2OD1zMz62PVI4KM7:TR?= NXXhWoE2W0GQR1XS
OS-RC-2 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M365dGlEPTB;MUOuPVUxOSEQvF2= Mk\OV2FPT0WU
GCT MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfGO|VRUUN3ME2xN{46Pjl5IN88US=> MYXTRW5ITVJ?
NB17 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG3UY9KSzVyPUG0MlA5PSEQvF2= NYLkSVJuW0GQR1XS
NCI-H2030 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF2LkG0OlUh|ryP MWfTRW5ITVJ?
HC-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF2LkKwPFch|ryP MVjTRW5ITVJ?
QIMR-WIL MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XYOmlEPTB;MUSuN|QyOiEQvF2= NI\NSZdUSU6JRWK=
Capan-2 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK2TWM2OD1zND6zO|E1KM7:TR?= MYLTRW5ITVJ?
BALL-1 NI\SPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnVOm5KSzVyPUG0MlQ3PjVizszN MkOyV2FPT0WU
LS-1034 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HFZWlEPTB;MUSuOlE2OiEQvF2= M4e0bXNCVkeHUh?=
U-118-MG NXPaUXRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDsTWM2OD1zND62N|Eh|ryP M4\VNnNCVkeHUh?=
NCI-H630 NEK0fndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nYVmlEPTB;MUSuOlU3QCEQvF2= NVq0bnFNW0GQR1XS
OVCAR-8 M2e5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILPOplKSzVyPUG0MlczODFizszN MnPOV2FPT0WU
NCI-H2347 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHXTWM2OD1zND64NlMh|ryP MlzIV2FPT0WU
BT-549 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF2LkiyPFQh|ryP NXn2U45GW0GQR1XS
LB831-BLC M1TO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHzeZpKSzVyPUG0Mlg6OzRizszN MWjTRW5ITVJ?
NCI-H661 NVXUbnRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrzTWM2OD1zND65OVkh|ryP NGG0V3lUSU6JRWK=
MKN7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Ls[GlEPTB;MUWuNFA6OyEQvF2= MXHTRW5ITVJ?
U-87-MG NFnNSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTO5hyUUN3ME2xOU4xQDl5IN88US=> MYHTRW5ITVJ?
OVCAR-4 NG\KWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrLTWM2OD1zNT6xOFI1KM7:TR?= M3zqTXNCVkeHUh?=
OE33 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj6[FFqUUN3ME2xOU4yPzFzIN88US=> M13vVXNCVkeHUh?=
EC-GI-10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjBTWM2OD1zNT6yN|U4KM7:TR?= MnHsV2FPT0WU
AM-38 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke2TWM2OD1zNT6yO|E4KM7:TR?= M3nWe3NCVkeHUh?=
NCI-H1563 NEHFSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD1zNT6zOFkh|ryP NEfjU45USU6JRWK=
SCC-4 M{\rR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW2SnFKSzVyPUG1MlQyODNizszN NHu2cXpUSU6JRWK=
Detroit562 NVrtS2ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjyNVZjUUN3ME2xOU41PTR5IN88US=> NGfTXldUSU6JRWK=
PC-14 M3exNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXCZWxKSzVyPUG1MlQ5PjZizszN M3jQ[HNCVkeHUh?=
ES3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7HTWM2OD1zNT61N|Yh|ryP MVzTRW5ITVJ?
OCI-AML2 NF\W[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K4XmlEPTB;MUWuO|YyPCEQvF2= MoCxV2FPT0WU
LU-134-A Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXyTWM2OD1zNT65NFE5KM7:TR?= MnHDV2FPT0WU
SAS MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTEPJBuUUN3ME2xOU46Ozd|IN88US=> NHjPfHhUSU6JRWK=
TGBC11TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL5TWM2OD1zNT65OFE1KM7:TR?= NVrYelB5W0GQR1XS
HOP-62 M{PMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF3Lkm1PVch|ryP MkDKV2FPT0WU
G-401 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW0TWM2OD1zNT65OlQ6KM7:TR?= MonzV2FPT0WU
NCI-H28 M{m5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD2[ZhsUUN3ME2xOk4xQDV4IN88US=> NX[xUItqW0GQR1XS
A204 NXz4fWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF4LkKwNFYh|ryP NFHhe5pUSU6JRWK=
NCI-H1299 NIrZSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF4LkKyPVEh|ryP NFmxdllUSU6JRWK=
VMRC-RCZ M4fQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M362e2lEPTB;MU[uNlU6OiEQvF2= M1[4e3NCVkeHUh?=
BxPC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nlPWlEPTB;MU[uNlg2PiEQvF2= MUjTRW5ITVJ?
NCI-H2228 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF4LkWxOVgh|ryP M1;6O3NCVkeHUh?=
NCI-H23 NULSVpBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF4Lk[wO|gh|ryP NX7xO|NvW0GQR1XS
NKM-1 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O3OmlEPTB;MUeuNFE5QSEQvF2= NYnsNoRGW0GQR1XS
KYSE-70 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTiOZNKSzVyPUG3MlI5QSEQvF2= MYnTRW5ITVJ?
BB49-HNC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\y[Wt4UUN3ME2xO{42Pjh4IN88US=> NHXQR5pUSU6JRWK=
SCC-15 NEL4d45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS3NJJKSzVyPUG3Mlg1PzNizszN M{XwdHNCVkeHUh?=
D-247MG NFfFVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF5LkmyOFch|ryP MXfTRW5ITVJ?
BB30-HNC MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S3bWlEPTB;MUiuNFMyQCEQvF2= NUC1VYdXW0GQR1XS
CAL-85-1 M{Lobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzwbHNJUUN3ME2xPE4yQDB7IN88US=> NH\sV2hUSU6JRWK=
HT-3 NVvRVXI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\pN|VtUUN3ME2xPE4{QTd5IN88US=> MmLLV2FPT0WU
KYSE-410 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfjSYtKSzVyPUG4MlQ2PzdizszN M4W4WnNCVkeHUh?=
SW982 M2PUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF6LkW2OFkh|ryP NF\Pe29USU6JRWK=
SW962 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnm[5pKSzVyPUG4MlU4ODJizszN NV[xTWZjW0GQR1XS
Ramos-2G6-4C10 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTqWFNKSzVyPUG4MlU6OjdizszN M4XaUXNCVkeHUh?=
OC-314 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHHSnJ3UUN3ME2xPE44Ozh2IN88US=> MkfzV2FPT0WU
LS-123 MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXKTWM2OD1zOD63PVAyKM7:TR?= NWTqe5l3W0GQR1XS
D-502MG NVG1VYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTiVldGUUN3ME2xPE45OTN7IN88US=> NXvkTG9OW0GQR1XS
RO82-W-1 NFPCU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXz[nRKSzVyPUG4MlgzQDhizszN MkWyV2FPT0WU
HuO9 M1T5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TOdWlEPTB;MUmuNVM4QSEQvF2= M{LzOHNCVkeHUh?=
ETK-1 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF7LkG4Nlch|ryP NVntXGhYW0GQR1XS
SNU-387 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfzTWM2OD1zOT6xPFg6KM7:TR?= NWm5c3NUW0GQR1XS
SW1573 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jLWGlEPTB;MUmuNVk3QSEQvF2= NE[3W2pUSU6JRWK=
NTERA-S-cl-D1 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXNTWM2OD1zOT6yNFA4KM7:TR?= NIrmSZhUSU6JRWK=
SF126 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojuTWM2OD1zOT6zOVAzKM7:TR?= MV3TRW5ITVJ?
Calu-3 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HLNWlEPTB;MUmuOFI{PyEQvF2= M3\nPXNCVkeHUh?=
NCI-H1048 M1jBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPYXYxKUUN3ME2yNE4{OjZ4IN88US=> NYnhd5BVW0GQR1XS
NCI-H226 M1PONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLQTVNKSzVyPUKwMlQ{QTlizszN NE\jT2VUSU6JRWK=
FTC-133 NVTlVmlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHXSIJ4UUN3ME2yNE41PzB|IN88US=> NEnKVHZUSU6JRWK=
SF539 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rGTmlEPTB;MkCuOVE4OiEQvF2= MlK0V2FPT0WU
TE-6 NVPZO216T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLWTWM2OD1{MD64NFY4KM7:TR?= MWPTRW5ITVJ?
UMC-11 M1vyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnvdndKSzVyPUKwMlkyPjRizszN NUjHe2FWW0GQR1XS
Becker MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7IVpBKSzVyPUKxMlEyOThizszN Mne4V2FPT0WU
KP-4 NYrVZVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33ZemlEPTB;MkGuNVE6PiEQvF2= MVnTRW5ITVJ?
ChaGo-K-1 NYTTc3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHtTWM2OD1{MT6zOlI4KM7:TR?= Ml\FV2FPT0WU
CFPAC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJzLkO4OVgh|ryP M1Hve3NCVkeHUh?=
A498 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJzLkWzNVIh|ryP M{mzXXNCVkeHUh?=
NCI-H1755 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJzLk[3OFEh|ryP MmDOV2FPT0WU
TI-73 NG\R[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;MUWlEPTB;MkKuN|I5KM7:TR?= MVfTRW5ITVJ?
NCI-H441 NWTXW4p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\OTWM2OD1{Mj61Olg6KM7:TR?= MoS3V2FPT0WU
CaR-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3NTWM2OD1{Mz6wNlE{KM7:TR?= NFvlWHVUSU6JRWK=
HCC1806 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD1{Mz6wOVg{KM7:TR?= NWrZUZJ2W0GQR1XS
SNU-449 NHuySG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfzOoFKSzVyPUKzMlMzQSEQvF2= NVmxU|ZQW0GQR1XS
EKVX MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ|LkO5NFkh|ryP Ml62V2FPT0WU
DMS-114 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme2TWM2OD1{Mz61O|Y2KM7:TR?= MUjTRW5ITVJ?
A704 NUPhPI1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ|Lk[xNFMh|ryP NIDnb4ZUSU6JRWK=
LC-2-ad NGDwRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXMTWM2OD1{Mz62NVQ4KM7:TR?= MXXTRW5ITVJ?
VM-CUB-1 NIP2T2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPnTWM2OD1{Mz63N|QyKM7:TR?= MmHGV2FPT0WU
PC-3 MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnhTG9sUUN3ME2yOE4xPTJ4IN88US=> MnHwV2FPT0WU
HEL NXLpPVNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XT[WlEPTB;MkSuNFg3PSEQvF2= NV36VpQ{W0GQR1XS
ABC-1 NXfQZ5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXwXHlRUUN3ME2yOE4zPzJ7IN88US=> NFi5VWdUSU6JRWK=
COLO-680N MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K4b2lEPTB;MkSuOFc3PCEQvF2= MluxV2FPT0WU
MZ1-PC M3Pibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLXbllyUUN3ME2yOE43QDdizszN M1HNR3NCVkeHUh?=
NCI-H69 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXzZZNKSzVyPUK0Mlc{PTRizszN M3K0ZXNCVkeHUh?=
TE-1 M3y2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ3LkC0PVkh|ryP NYTweIk5W0GQR1XS
EW-3 NYr3XJhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTUTWM2OD1{NT6xNVMh|ryP Mn75V2FPT0WU
PANC-08-13 M1HLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ3LkixNFMh|ryP Mn3SV2FPT0WU
NMC-G1 NFzndJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ixO2lEPTB;Mk[uNFA5QCEQvF2= M3GzUXNCVkeHUh?=
BT-20 M2GxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K0dWlEPTB;Mk[uOFU1OyEQvF2= NF61NYNUSU6JRWK=
TGBC24TKB M{LXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK1XXBjUUN3ME2yOk44OzNzIN88US=> MVTTRW5ITVJ?
TE-11 NInCcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXpVGR6UUN3ME2yOk46QDl3IN88US=> M2K4dnNCVkeHUh?=
ESS-1 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLlWZd5UUN3ME2yO{4{OjF4IN88US=> MWPTRW5ITVJ?
JVM-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nhWWlEPTB;MkeuOlQ4PSEQvF2= MXnTRW5ITVJ?
C3A NWe2dJViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvqfHBKSzVyPUK3Mlg1QTZizszN MWPTRW5ITVJ?
MDA-MB-157 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\MZmtKSzVyPUK3Mlg4PTNizszN MUDTRW5ITVJ?
KLE M{nLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPLTWM2OD1{OD6xNFU5KM7:TR?= NGT2coRUSU6JRWK=
ES1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJ6LkG4N|gh|ryP NVjScotVW0GQR1XS
CAL-120 M4\DV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHLPGpKSzVyPUK4MlM6QTlizszN M1nCXnNCVkeHUh?=
NCI-N87 Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ6LkWxNFUh|ryP MVTTRW5ITVJ?
RPMI-8226 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r2U2lEPTB;MkmuNVg1OyEQvF2= NVW2PWtbW0GQR1XS
COR-L88 NVLNXZF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGewR2RKSzVyPUK5MlI1OTlizszN NUmw[2lzW0GQR1XS
UACC-893 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHjc4NKSzVyPUK5MlMyOzdizszN Mk[0V2FPT0WU
C8166 M16wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HwW2lEPTB;MkmuPVk6PiEQvF2= NXz6cXZWW0GQR1XS
J82 NXn1[GVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X6S2lEPTB;M{CuPFE1PyEQvF2= NYPCUJo2W0GQR1XS
PFSK-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNzLkC2OVkh|ryP NWX3NWtvW0GQR1XS
COLO-684 NXS2cm03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPWTWM2OD1|MT60N|c1KM7:TR?= MVHTRW5ITVJ?
CAL-72 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\yTWM2OD1|MT61O|I6KM7:TR?= NYfONZk1W0GQR1XS
SNB75 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvPbIhJUUN3ME2zNU45QTdizszN MontV2FPT0WU
MDA-MB-415 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G0dGlEPTB;M{GuPVc3OiEQvF2= NXqxOopGW0GQR1XS
SiHa M3jXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH3TWM2OD1|Mj60O|EyKM7:TR?= M4HEXXNCVkeHUh?=
NCI-H1648 NUf1WIw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHvW4VnUUN3ME2zNk46OzR3IN88US=> M4nOTXNCVkeHUh?=
EFO-21 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDJd5BKSzVyPUOzMlAxPSEQvF2= NFWwPWlUSU6JRWK=
HCC38 NFXpWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN|LkO4OFEh|ryP M2n1dnNCVkeHUh?=
IA-LM NIC1OoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\mTW9KSzVyPUOzMlc5QDlizszN NHfTZVBUSU6JRWK=
CTV-1 NX\4eHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljHTWM2OD1|Mz65O|g3KM7:TR?= NEX2cFBUSU6JRWK=
NCI-H446 NULQTY9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnuWlhtUUN3ME2zOE4zPjh7IN88US=> NUCzRYtJW0GQR1XS
IST-SL1 NIGxUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzycIRKSzVyPUO0Mlc1ODhizszN NUnrc4pmW0GQR1XS
EW-22 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTN2Lke3OVkh|ryP MUXTRW5ITVJ?
JEG-3 NXzJdnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm2ZWtKSzVyPUO2MlE4PjZizszN Mo\KV2FPT0WU
LU-65 M{XrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\KcnI{UUN3ME2zOk4zQTh3IN88US=> M3;Pd3NCVkeHUh?=
NCI-H596 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PRfWlEPTB;M{[uPVU6OSEQvF2= NWX1VmF3W0GQR1XS
KNS-81-FD M2LpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DlRmlEPTB;M{euNVQ2KM7:TR?= NHi5bVJUSU6JRWK=
NCI-H1793 NV7lbIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC2UYJKSzVyPUO3MlcxQDZizszN M{f0RXNCVkeHUh?=
NCI-H460 M1zjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PhNWlEPTB;M{iuNFg4OyEQvF2= NXXycGZQW0GQR1XS
MPP-89 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTHPWxKSzVyPUO5MlU5QDZizszN MkfnV2FPT0WU
D-542MG MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvJTWM2OD1|OT64OFM3KM7:TR?= M3jMdHNCVkeHUh?=
JAR NUjaemZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQbIhKSzVyPUSwMlQ4ODVizszN MWTTRW5ITVJ?
NCI-H209 M36xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;XTWM2OD12MD62O|ch|ryP MYDTRW5ITVJ?
G-402 NXHWRZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWz[FhHUUN3ME20NU4{QTl|IN88US=> NG\S[IpUSU6JRWK=
IST-MES1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTR{LkG5N|Uh|ryP MnnIV2FPT0WU
Daoy NXe1SIx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2[4h4UUN3ME20Nk42PDdzIN88US=> NHjKemtUSU6JRWK=
EW-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnQfIUzUUN3ME20N{4yOjFzIN88US=> NX\YRnNzW0GQR1XS
Saos-2 M{jveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT6bmRUUUN3ME20N{4yPTN5IN88US=> Mnj3V2FPT0WU
no-10 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS5TWM2OD12Mz6xO|AzKM7:TR?= MX3TRW5ITVJ?
HCC1395 NFfGXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XWOmlEPTB;NEOuOFY1PCEQvF2= NYHHZWxxW0GQR1XS
HCE-4 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z5TmlEPTB;NEOuO|Y3PCEQvF2= NVqwNoYzW0GQR1XS
EW-1 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTR|LkiwOFkh|ryP NXfFblBbW0GQR1XS
OCUB-M NV3VS3F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr0TWM2OD12ND6zOlM5KM7:TR?= M4\1UHNCVkeHUh?=
IGR-1 M4\xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HLfmlEPTB;NESuOFEyPSEQvF2= NHnHSnBUSU6JRWK=
NCI-H1838 M4ezUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P5WWlEPTB;NESuOFM1QSEQvF2= MkHjV2FPT0WU
NCI-H2405 NGrveW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2yTWM2OD12ND61N|Qh|ryP M4G2T3NCVkeHUh?=
GB-1 NXz3SppoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLiTWM2OD12ND63OFY{KM7:TR?= M{\xcnNCVkeHUh?=
MG-63 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3kVYY{UUN3ME20Ok4xPjl4IN88US=> NHXTTmFUSU6JRWK=
KP-N-YN NFX6SXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nYcmlEPTB;NE[uOFY4QSEQvF2= NGHiRVVUSU6JRWK=
no-11 NIDJR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR5LkCyOFQh|ryP M1W1OnNCVkeHUh?=
SW948 NGXzcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLwZmV3UUN3ME20O{4{Ozd5IN88US=> MX3TRW5ITVJ?
CAMA-1 M4DpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XBcmlEPTB;NEeuN|Q{QCEQvF2= NFvGXXRUSU6JRWK=
HCC1187 MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Tz[WlEPTB;NEeuOVEh|ryP NEDqUXNUSU6JRWK=
D-392MG NFHJdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK0TWM2OD12Nz62OVE3KM7:TR?= M2T5WHNCVkeHUh?=
647-V MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H3NWlEPTB;NEmuN|QyPCEQvF2= MULTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID